+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Parkinson's Disease Therapeutics Market Research Report by Type, Drug Class, Distribution Channel, End Use, State - United States Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 143 Pages
  • October 2022
  • Region: United States
  • 360iResearch™
  • ID: 5134184
UP TO OFF until Dec 31st 2022
The United States Parkinson's Disease Therapeutics Market size was estimated at USD 1,162.22 million in 2021, USD 1,319.72 million in 2022, and is projected to grow at a CAGR of 10.00% to reach USD 2,059.74 million by 2027.

Market Statistics:

The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Parkinson's Disease Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Type, the market was studied across Intestinal Infusion, Oral, Subcutaneous, and Transdermal.
  • Based on Drug Class, the market was studied across Anticholinergic, Carbidopa/Levodopa, COMT Inhibitor, Dopamine Receptor Agonist, and MAO Inhibitor.
  • Based on Distribution Channel, the market was studied across Hospital Pharmacy, Online Pharmacy, and Retailer Pharmacy.
  • Based on End Use, the market was studied across Clinic and Hospital.
  • Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. This ongoing research amplifies This research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:

The publisher continuously monitors and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Parkinson's Disease Therapeutics market considering the current update on the conflict and its global response.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Parkinson's Disease Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor's strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Parkinson's Disease Therapeutics Market, including Abbvie, Inc., ACADIA Pharmaceuticals, Inc., Amneal Pharmaceuticals, Inc., Apotex, Inc., Bausch Health Companies, Inc., Boehringer Ingelheim International GmbH, Cipla, Inc., Daiichi Sankyo Company, H. Lundbeck A/S, Mylan N.V., Novartis AG, Orion Corporation, Par Pharmaceutical by Endo International PLC, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., and WOCKHARDT.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Parkinson's Disease Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Parkinson's Disease Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Parkinson's Disease Therapeutics Market?
4. What is the competitive strategic window for opportunities in the United States Parkinson's Disease Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the United States Parkinson's Disease Therapeutics Market?
6. What is the market share of the leading vendors in the United States Parkinson's Disease Therapeutics Market?
7. What modes and strategic moves are considered suitable for entering the United States Parkinson's Disease Therapeutics Market?
Frequently Asked Questions about the U.S. Parkinson Disease Therapeutics Market

What is the estimated value of the U.S. Parkinson Disease Therapeutics Market?

The U.S. Parkinson Disease Therapeutics Market was estimated to be valued at $1162.22 Million in 2021.

What is the growth rate of the U.S. Parkinson Disease Therapeutics Market?

The growth rate of the U.S. Parkinson Disease Therapeutics Market is 10.0%, with an estimated value of $2059.74 Million by 2027.

What is the forecasted size of the U.S. Parkinson Disease Therapeutics Market?

The U.S. Parkinson Disease Therapeutics Market is estimated to be worth $2059.74 Million by 2027.

Who are the key companies in the U.S. Parkinson Disease Therapeutics Market?

Key companies in the U.S. Parkinson Disease Therapeutics Market include Abbvie, Inc., ACADIA Pharmaceuticals, Inc., Amneal Pharmaceuticals, Inc., Apotex, Inc., Bausch Health Companies, Inc., Boehringer Ingelheim International GmbH, Cipla, Inc., Daiichi Sankyo Company and Mylan N.V..

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
6. Parkinson's Disease Therapeutics Market, by Type
6.1. Introduction
6.2. Intestinal Infusion
6.3. Oral
6.4. Subcutaneous
6.5. Transdermal
7. Parkinson's Disease Therapeutics Market, by Drug Class
7.1. Introduction
7.2. Anticholinergic
7.3. Carbidopa/Levodopa
7.4. COMT Inhibitor
7.5. Dopamine Receptor Agonist
7.6. MAO Inhibitor
8. Parkinson's Disease Therapeutics Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacy
8.3. Online Pharmacy
8.4. Retailer Pharmacy
9. Parkinson's Disease Therapeutics Market, by End Use
9.1. Introduction
9.2. Clinic
9.3. Hospital
10. California Parkinson's Disease Therapeutics Market
10.1. Introduction
11. Florida Parkinson's Disease Therapeutics Market
11.1. Introduction
12. Illinois Parkinson's Disease Therapeutics Market
12.1. Introduction
13. New York Parkinson's Disease Therapeutics Market
13.1. Introduction
14. Ohio Parkinson's Disease Therapeutics Market
14.1. Introduction
15. Pennsylvania Parkinson's Disease Therapeutics Market
15.1. Introduction
16. Texas Parkinson's Disease Therapeutics Market
16.1. Introduction
17. Competitive Landscape
17.1. FPNV Positioning Matrix
17.1.1. Quadrants
17.1.2. Business Strategy
17.1.3. Product Satisfaction
17.2. Market Ranking Analysis, By Key Player
17.3. Market Share Analysis, By Key Player
17.4. Competitive Scenario
17.4.1. Merger & Acquisition
17.4.2. Agreement, Collaboration, & Partnership
17.4.3. New Product Launch & Enhancement
17.4.4. Investment & Funding
17.4.5. Award, Recognition, & Expansion
18. Company Usability Profiles
18.1. Abbvie, Inc.
18.1.1. Business Overview
18.1.2. Key Executives
18.1.3. Product & Services
18.2. ACADIA Pharmaceuticals, Inc.
18.2.1. Business Overview
18.2.2. Key Executives
18.2.3. Product & Services
18.3. Amneal Pharmaceuticals, Inc.
18.3.1. Business Overview
18.3.2. Key Executives
18.3.3. Product & Services
18.4. Apotex, Inc.
18.4.1. Business Overview
18.4.2. Key Executives
18.4.3. Product & Services
18.5. Bausch Health Companies, Inc.
18.5.1. Business Overview
18.5.2. Key Executives
18.5.3. Product & Services
18.6. Boehringer Ingelheim International GmbH
18.6.1. Business Overview
18.6.2. Key Executives
18.6.3. Product & Services
18.7. Cipla, Inc.
18.7.1. Business Overview
18.7.2. Key Executives
18.7.3. Product & Services
18.8. Daiichi Sankyo Company
18.8.1. Business Overview
18.8.2. Key Executives
18.8.3. Product & Services
18.9. H. Lundbeck A/S
18.9.1. Business Overview
18.9.2. Key Executives
18.9.3. Product & Services
18.10. Mylan N.V.
18.10.1. Business Overview
18.10.2. Key Executives
18.10.3. Product & Services
18.11. Novartis AG
18.11.1. Business Overview
18.11.2. Key Executives
18.11.3. Product & Services
18.12. Orion Corporation
18.12.1. Business Overview
18.12.2. Key Executives
18.12.3. Product & Services
18.13. Par Pharmaceutical by Endo International PLC
18.13.1. Business Overview
18.13.2. Key Executives
18.13.3. Product & Services
18.14. Sun Pharmaceutical Industries Limited
18.14.1. Business Overview
18.14.2. Key Executives
18.14.3. Product & Services
18.15. Teva Pharmaceutical Industries Ltd.
18.15.1. Business Overview
18.15.2. Key Executives
18.15.3. Product & Services
18.16. UCB S.A.
18.16.1. Business Overview
18.16.2. Key Executives
18.16.3. Product & Services
18.17. WOCKHARDT
18.17.1. Business Overview
18.17.2. Key Executives
18.17.3. Product & Services
19. Appendix
19.1. Discussion Guide
19.2. License & Pricing
List of Figures
FIGURE 1. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2021 VS 2027
FIGURE 3. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 4. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 5. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 6. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2027
FIGURE 7. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET DYNAMICS
FIGURE 8. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2021 VS 2027 (%)
FIGURE 9. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 10. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY TYPE, 2027
FIGURE 11. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INTESTINAL INFUSION, 2018-2027 (USD MILLION)
FIGURE 12. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2027 (USD MILLION)
FIGURE 13. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, 2018-2027 (USD MILLION)
FIGURE 14. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, 2018-2027 (USD MILLION)
FIGURE 15. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (%)
FIGURE 16. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2021 VS 2027 (USD MILLION)
FIGURE 17. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY DRUG CLASS, 2027
FIGURE 18. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGIC, 2018-2027 (USD MILLION)
FIGURE 19. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CARBIDOPA/LEVODOPA, 2018-2027 (USD MILLION)
FIGURE 20. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITOR, 2018-2027 (USD MILLION)
FIGURE 21. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR AGONIST, 2018-2027 (USD MILLION)
FIGURE 22. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO INHIBITOR, 2018-2027 (USD MILLION)
FIGURE 23. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (%)
FIGURE 24. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2021 VS 2027 (USD MILLION)
FIGURE 25. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY DISTRIBUTION CHANNEL, 2027
FIGURE 26. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2027 (USD MILLION)
FIGURE 27. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, 2018-2027 (USD MILLION)
FIGURE 28. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAILER PHARMACY, 2018-2027 (USD MILLION)
FIGURE 29. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2021 VS 2027 (%)
FIGURE 30. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2021 VS 2027 (USD MILLION)
FIGURE 31. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY END USE, 2027
FIGURE 32. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINIC, 2018-2027 (USD MILLION)
FIGURE 33. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL, 2018-2027 (USD MILLION)
FIGURE 34. CALIFORNIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 35. FLORIDA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 36. ILLINOIS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 37. NEW YORK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 38. OHIO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 39. PENNSYLVANIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 40. TEXAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 41. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 42. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 43. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2021
List of Tables
TABLE 1. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2021
TABLE 3. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 4. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2027 (USD MILLION)
TABLE 5. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 6. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INTESTINAL INFUSION, 2018-2027 (USD MILLION)
TABLE 7. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INTESTINAL INFUSION, BY STATE, 2018-2027 (USD MILLION)
TABLE 8. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2027 (USD MILLION)
TABLE 9. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY STATE, 2018-2027 (USD MILLION)
TABLE 10. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, 2018-2027 (USD MILLION)
TABLE 11. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY STATE, 2018-2027 (USD MILLION)
TABLE 12. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, 2018-2027 (USD MILLION)
TABLE 13. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY STATE, 2018-2027 (USD MILLION)
TABLE 14. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 15. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGIC, 2018-2027 (USD MILLION)
TABLE 16. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGIC, BY STATE, 2018-2027 (USD MILLION)
TABLE 17. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CARBIDOPA/LEVODOPA, 2018-2027 (USD MILLION)
TABLE 18. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CARBIDOPA/LEVODOPA, BY STATE, 2018-2027 (USD MILLION)
TABLE 19. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITOR, 2018-2027 (USD MILLION)
TABLE 20. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITOR, BY STATE, 2018-2027 (USD MILLION)
TABLE 21. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR AGONIST, 2018-2027 (USD MILLION)
TABLE 22. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR AGONIST, BY STATE, 2018-2027 (USD MILLION)
TABLE 23. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO INHIBITOR, 2018-2027 (USD MILLION)
TABLE 24. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO INHIBITOR, BY STATE, 2018-2027 (USD MILLION)
TABLE 25. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 26. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2027 (USD MILLION)
TABLE 27. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY STATE, 2018-2027 (USD MILLION)
TABLE 28. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, 2018-2027 (USD MILLION)
TABLE 29. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY STATE, 2018-2027 (USD MILLION)
TABLE 30. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAILER PHARMACY, 2018-2027 (USD MILLION)
TABLE 31. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAILER PHARMACY, BY STATE, 2018-2027 (USD MILLION)
TABLE 32. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2027 (USD MILLION)
TABLE 33. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINIC, 2018-2027 (USD MILLION)
TABLE 34. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINIC, BY STATE, 2018-2027 (USD MILLION)
TABLE 35. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL, 2018-2027 (USD MILLION)
TABLE 36. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY STATE, 2018-2027 (USD MILLION)
TABLE 37. CALIFORNIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 38. CALIFORNIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 39. CALIFORNIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 40. CALIFORNIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 41. CALIFORNIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2027 (USD MILLION)
TABLE 42. FLORIDA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 43. FLORIDA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 44. FLORIDA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 45. FLORIDA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 46. FLORIDA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2027 (USD MILLION)
TABLE 47. ILLINOIS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 48. ILLINOIS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 49. ILLINOIS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 50. ILLINOIS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 51. ILLINOIS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2027 (USD MILLION)
TABLE 52. NEW YORK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 53. NEW YORK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 54. NEW YORK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 55. NEW YORK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 56. NEW YORK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2027 (USD MILLION)
TABLE 57. OHIO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 58. OHIO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 59. OHIO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 60. OHIO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 61. OHIO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2027 (USD MILLION)
TABLE 62. PENNSYLVANIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 63. PENNSYLVANIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 64. PENNSYLVANIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 65. PENNSYLVANIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 66. PENNSYLVANIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2027 (USD MILLION)
TABLE 67. TEXAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 68. TEXAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2027 (USD MILLION)
TABLE 69. TEXAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2027 (USD MILLION)
TABLE 70. TEXAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 71. TEXAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2027 (USD MILLION)
TABLE 72. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 73. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 74. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 75. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET RANKING, BY KEY PLAYER, 2021
TABLE 76. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2021
TABLE 77. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET MERGER & ACQUISITION
TABLE 78. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 79. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 80. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET INVESTMENT & FUNDING
TABLE 81. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 82. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET: LICENSE & PRICING

Companies Mentioned

  • Abbvie, Inc.
  • ACADIA Pharmaceuticals, Inc.
  • Amneal Pharmaceuticals, Inc.
  • Apotex, Inc.
  • Bausch Health Companies, Inc.
  • Boehringer Ingelheim International GmbH
  • Cipla, Inc.
  • Daiichi Sankyo Company
  • H. Lundbeck A/S
  • Mylan N.V.
  • Novartis AG
  • Orion Corporation
  • Par Pharmaceutical by Endo International PLC
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.
  • WOCKHARDT

Methodology

Loading
LOADING...